Subscribe To
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Fxwirepro :eur/nzd consolidates around 1.7850, maintains bullish bias
EUR/NZD rose higher on Friday on as broad based New Zealand dollar selling drove EUR/NZD higher. The pa...
October 13, 2023, 8:14 pm
Pound sterling price news and forecast: gbp/usd extends backslide for friday, aimed for 1.21
Following an earlier recovery attempt, GBP/USD turned south and declined below 1.2100 in the second half of the ...
October 13, 2023, 8:14 pm
Mideast tensions send the swiss franc, oil and gold sharply higher
Univ of Mich: Short- and longer-run inflation expectations surge (1-year rises to 3.8% and 5-10 year rise to 3.0%) Consumer sentiment plunges from 68....
October 13, 2023, 6:00 pm
Eur/gbp set to close flat below the 0.8650 mark
EUR/USD lost almost a hundred pips on Thursday on the back of a stronger US Dollar. The pair is consoli...
October 12, 2023, 10:29 pm
Birkenstock's stock loses footing in second day on wall street
Shares of Birkenstock dropped 6% on Thursday, deepening losses after the German luxury sandal seller stumbled the day before in its Wall Street debut....
October 12, 2023, 2:51 pm
First solar stock boost by barclays upgrade and ‘solar uncommon dialog' pact to boost large-scale projects
First Solar Inc.'s FSLR, +1.18% stock was up by 0.6% on Thursday on the heels of an upgrade to overweig...
October 12, 2023, 10:02 am
Pound sterling price news and forecast: gbp/usd mostly flat for wednesday
The GBP/USD pair gains some positive traction for the sixth successive day on Wednesday and climbs to a...
October 11, 2023, 7:29 pm
Birkenstock finishes first us trading day on the back foot
Birkenstock finished its first trading day on the New York Stock Exchange Wednesday 12.6% lower. Shares...
October 11, 2023, 4:20 pm
Natural gas prices rising further
Market movers today Today is a quiet day on the data front and focus will likely remain on developments...
October 11, 2023, 6:07 am
Jim cramer is back with a jab on apex crypto: ‘mr bitcoin is about to go down big’— inverse cramer responds
CNBC TV host Jim Cramer on Tuesday once again took a dig at Bitcoin’s (CRYPTO: BTC) future, suggestin...
October 11, 2023, 4:29 am
Ecb's knot speaking wednesday on financial stability
I only have Knot on the European Central Bank speaking circuit today. Its not unusual at all for others to pop up though. 0815 GMT / 0415 US Eastern t...
October 11, 2023, 2:28 am